{
    "ticker": "MESO",
    "name": "Mesoblast Limited",
    "description": "Mesoblast Limited is a global leader in developing innovative cellular medicines aimed at addressing significant unmet medical needs. Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast specializes in regenerative medicine, particularly focusing on the development of therapies derived from its proprietary allogeneic mesenchymal stem cells. The company's flagship product, remestemcel-L, is designed to treat a range of inflammatory and degenerative diseases, including critical COVID-19 complications, heart failure, and other serious conditions. Mesoblast's advanced therapeutic approach leverages its expertise in cell therapy to create treatments that can potentially improve patient outcomes and reduce healthcare costs. The company is committed to conducting rigorous clinical trials to validate its therapies, and it collaborates with leading medical institutions worldwide to ensure the efficacy and safety of its products. With a strong intellectual property portfolio and a dedication to innovation, Mesoblast aims to transform the field of medicine through the power of regenerative therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Melbourne, Australia",
    "founded": "2004",
    "website": "https://www.mesoblast.com",
    "ceo": "Silviu Itescu",
    "social_media": {
        "twitter": "https://twitter.com/Mesoblast",
        "linkedin": "https://www.linkedin.com/company/mesoblast-limited/"
    },
    "investor_relations": "https://www.mesoblast.com/investors",
    "key_executives": [
        {
            "name": "Silviu Itescu",
            "position": "CEO"
        },
        {
            "name": "Paul L. A. M. C. O'Connell",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cellular Therapies",
            "products": [
                "remestemcel-L",
                "MPC-150-IM"
            ]
        }
    ],
    "seo": {
        "meta_title": "Mesoblast Limited | Innovating Regenerative Medicines",
        "meta_description": "Explore Mesoblast Limited, a leader in cellular medicine focused on regenerative therapies for serious diseases. Learn about our innovative products and commitment to healthcare.",
        "keywords": [
            "Mesoblast",
            "Regenerative Medicine",
            "Cell Therapy",
            "Mesenchymal Stem Cells",
            "Remestemcel-L"
        ]
    },
    "faq": [
        {
            "question": "What is Mesoblast known for?",
            "answer": "Mesoblast is known for developing innovative cellular medicines, particularly therapies based on mesenchymal stem cells."
        },
        {
            "question": "Who is the CEO of Mesoblast?",
            "answer": "Silviu Itescu is the CEO of Mesoblast Limited."
        },
        {
            "question": "Where is Mesoblast headquartered?",
            "answer": "Mesoblast is headquartered in Melbourne, Australia."
        },
        {
            "question": "What are Mesoblast's main products?",
            "answer": "Mesoblast's main products include remestemcel-L and MPC-150-IM, aimed at treating various serious health conditions."
        },
        {
            "question": "When was Mesoblast founded?",
            "answer": "Mesoblast was founded in 2004."
        }
    ],
    "competitors": [
        "BLUE",
        "CELG",
        "BMRN"
    ],
    "related_stocks": [
        "GILD",
        "AMGN",
        "REGN",
        "VRTX"
    ]
}